⬤ Loading…
Gland Pharma Ltd
…
NSE: GLAND BSE: 543245 INE068V01023 Healthcare Pharma 🔎 Screen
NIFTY 500 Smallcap 50 Smallcap 100 Smallcap 250 Pharma MNC +1 more
₹55,016 Cr
Market Cap
44.5
P/E
4.65
PEG
15.1%
ROCE
10.7%
ROE
0.03
D/E
27.3%
OPM
0.0%
% from 52W High
95
α RS
🔍 GLAND is showing a multi-screen setup because it matches 10 of 37 tracked screener presets, RS Rating is 95 (top decile vs Nifty), an ECS of 51.4 last quarter (real cash backing the earnings), and it has maintained a 94-day Stage 2 momentum persistence. The main caution: the current price already looks stretched relative to its own trading history. Net: Mixed signal stack, not a recommendation. ? Conviction RS Rating ECS Momentum Streaks Valuation
Sources
Conviction 10/37 · RS Rating 95 · ECS 51.4 · Stage 2 streak: 94d · Valuation: stretched
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides

Investment Brief

Evidence through Sep 2026

The business

Customers are innovators and specialty pharmaceutical companies in regulated markets; US revenue for the half-year was ₹2,161 crore, up 37%, Europe and other regulated markets revenue was ₹411 crore, up 23%, rest-of-world revenue was ₹204 crore and India revenue was ₹38.7 crore.

Revenue · Sep 2026
₹1,834 cr
▲ 23.3% vs a year ago
EBITDA · Sep 2026
₹484 cr
▲ 54.1% vs a year ago
Profit after tax · Sep 2026
₹291 cr
▲ 58.2% vs a year ago
EBITDA margin · trailing 12 months
27.2%
Price-to-earnings · trailing 12 months
44.5x
Promoter holding · Sep 2026
45.8%
−6.0 pp vs Jun 2026

What is changing

  • CDMO revenue grew 31% year-on-year to ₹823 crore and contributed about 45% of total revenue, driven by commercial supply of previously signed contracts, new launches and new development and manufacturing partnerships.
  • US revenue grew 42% year-on-year to ₹1,180 crore in the quarter and 37% to ₹2,161 crore in the half-year, helped by new product launches and newer CDMO business.

Recent events

In Sep 2026, promoter holding fell by 6.0 percentage points versus the previous quarter.
On 4 Sep 2026, Fosun Pharma Industrial Pte. Ltd. disclosed a disposal of 6.0% of the company.

Catalysts

CatalystTimingSizeWhat has to go right
US FDA inspection of the additional bag manufacturing line, after which products from the line could be commercialized and the capacity constraint eased.——The inspection has to conclude so that the line can be used for commercial supply.
NUPCO tender results from Saudi Arabia, which management says are delayed.——The tender has to be announced; management says it has participated with about 13 products and is confident of winning products in that segment.

Strengths

  • CDMO growth and mix
    CDMO revenue grew 31% year-on-year to ₹823 crore and contributed about 45% of total revenue, with margins described as better than the regular business by about 5% to 10%.
  • US portfolio expansion
    The company launched products in the US in the quarter, filed 11 ANDAs and received 10 approvals, bringing cumulative US ANDA filings to 399 with 350 approved and 49 pending.

Risks

  • Capacity constraints
    Management says it is struggling for capacity in ophthalmic, bags and liquid vials, with liquid vial utilization already at 92% and anticipated at close to 102% next year.
  • Tender and supply timing
    Performance was impacted by market-specific supply and tender dynamics, especially the delay of NUPCO tender results from Saudi Arabia, and by lower volumes due to delayed tender business in the Middle East.

Competitive position

On operating margin, the company's 27.3% is above the peer median of 13.5% for the 241 companies in the peer group with a value, ranking 37 of 241.

MetricGLANDPeer medianRank
Operating margin27.3%13.5%37 of 241
Return on capital employed15.1%12.5%97 of 242
Return on equity10.7%10.5%115 of 236

Compared with 248 companies in Pharmaceuticals & Biotechnology (medians; data as of 15 Nov 2026). Rank 1 is best, except price multiples, where 1 is lowest.

Latest quarter

Sep 2026Latestvs year agovs prior quarter
Revenue₹1,834 cr23.3%1.9%
EBITDA₹484 cr54.1%-1.0%
Profit after tax₹291 cr58.2%-8.2%
  • Over the trailing twelve months revenue was ₹7,072 crore, EBITDA was ₹1,921 crore and profit after tax was ₹1,236 crore, an EBITDA margin of 27.2%.

What the price requires

Market capitalisation ₹55,016 cr · trailing 12-month profit after tax ₹1,236 cr · price-to-earnings 44.5x

Assumed yearly return to shareholdersProfit needed at the endImplied yearly profit growth
12.0%₹1,737 cr12.0%

A calculation, not a forecast: 3-year horizon, the multiple unchanged and a constant share count.

Ownership and deals

HolderSep 2026Jun 2026Change
Promoters45.8%51.8%−6.0 pp
Foreign institutions10.4%8.7%+1.6 pp
Domestic institutions33.2%30.4%+2.8 pp
  • On 4 Sep 2026, Fosun Pharma Industrial Pte. Ltd. disclosed a disposal of 6.0% of the company.
Premium adds the bottom line, every strength, risk and catalyst with its sources, the guidance-versus-actuals section where it applies, and the full calculation set. Log in or see Premium

Facts from company filings, exchange data and company documents, with calculations shown. Educational information; not investment advice.

Open on its own page →

📈 Price History
Ratio Health
— Excellent
— Good
— Average
— Poor
By Category
Shareholding
About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

✓ Strengths 2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.1%
! Concerns 3
  • Stock is trading at 5.15 times its book value
  • Promoter holding has decreased over last quarter: -6.02%
  • Company has a low return on equity of 9.29% over last 3 years.
Key Ratios Snapshot
📊 Peer Medians
📈 Growth Pattern
📊 Quick Scorecard
Loading…
🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
Strong quarter: Revenue +20% YoY to ₹1,800.3 Cr and PAT +47% YoY on US-led launches and margin expansion, though PAT fell 14% sequentially. quarter Investor Presentation One-Pager? Jun 2026
Revenue
₹1,800.3 Cr
+20% YoY; +3% QoQ
EBITDA Margin
27%
+300 bps YoY; -200 bps QoQ
PAT
₹317.0 Cr
+47% YoY; -14% QoQ
US Revenue
₹981.0 Cr
+32% YoY; 54% of total revenue
What Went Right
  • Consolidated revenue grew 20% YoY to ₹1,800.3 Cr, with CDMO +20% YoY to ₹891.5 Cr and B2B +19% YoY to ₹908.8 Cr.
  • PAT jumped 47% YoY to ₹317.0 Cr; Adj. EBITDA rose 37% YoY to ₹510.2 Cr, with margin up ~300 bps YoY to 28%.
  • US revenue grew 32% YoY to ₹981.0 Cr, helped by 4 US launches including Multi-Vitamin and Leucovorin calcium.
  • 7 ANDAs approved in Q1 FY27, taking cumulative US approvals to 342; RTU bag portfolio has 18 approvals and addresses ~$644 mn US market opportunity.
  • CDMO partnership with a global pharma carries ~$90–100 mn annualized revenue potential once commercialized, with revenue expected from CY2029.
What to Watch
  • Other Core Markets (Canada, Australia, NZ) revenue fell 28% YoY to ₹53.4 Cr, with CDMO there down 45% YoY to ₹19.9 Cr on volume decline.
  • India B2B fell 36% YoY to ₹18.3 Cr on lower Enoxaparin sales; total India revenue only grew 12% YoY because CDMO India rose 56% YoY.
  • Sequential momentum weakened: revenue +3% QoQ, EBITDA -4% QoQ, PAT -14% QoQ; other income dropped 45% QoQ to ₹61.2 Cr.
  • US B2B revenue fell ~5% QoQ to ₹715.7 Cr, suggesting pricing/volume pressure despite strong YoY growth.
  • B2B total declined 3% QoQ to ₹908.8 Cr; revenue is now heavily concentrated in US/Europe at 76% of mix.
Management Guidance
  • CDMO partnership with a global pharmaceutical company: annualized revenue potential expected to be approximately USD 90–100 million once all products are commercialized; technology transfer planned for completion within 2 years, revenues expected to commence from CY2029.
Investor Lens
The long-term thesis remains intact, supported by US complex-injectable execution: US revenue grew 32% YoY to ₹981.0 Cr, 7 ANDAs were approved, and PAT jumped 47% YoY to ₹317.0 Cr. But near-term momentum softened — PAT fell 14% QoQ, B2B declined 3% QoQ, and Other Core Markets shrank 28% YoY. With 76% of revenue from US/Europe, a slowdown or price erosion in US B2B would be a disproportionate risk. The pipeline is materially stronger (RTU 18 approvals, 15 co-development products, CDMO partnership with $90–100 mn potential), yet the CDMO partnership contributes no revenue before CY2029. Next quarter, watch US B2B volume, CDMO launch ramp beyond Dalbavancin/Multi-Vitamin, and stabilization in India B2B/Other Core Markets.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Q1 revenue +19.5%, PAT +47.4% YoY, but QoQ PAT -13.6%
Revenue
Revenue grew 19.5% YoY to ₹1,800 Cr, with a 3.3% QoQ uptick. Growth was broad-based across markets.
Profitability
Net profit jumped 47.4% YoY to ₹317 Cr, though it fell 13.6% QoQ. EPS came in at ₹19.21 vs ₹13.08 in last year's quarter.
Margins
Operating margin expanded 300 bps YoY to 27%, but contracted 200 bps QoQ from 29%. Higher operating leverage aided YoY margin improvement.
Key Risks
PE of 47x implies high growth expectations; QoQ margin and profit decline signals near-term slowdown. ROCE at 15.1% and ROE at 10.7% are modest, and any growth hiccup could pressure valuation.
Outlook
Revenue trajectory remains positive with 19.5% YoY growth, but margin stability is key. Continuation of cost discipline and product launches will drive future performance.
Generated by AI · Jun 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Documents.

Access concall transcripts, annual reports, credit ratings, and investor presentations.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, SAST trigger, pledge change, concall, and corporate action for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Forensic Report.

A filings-based disclosure review of this company's most recent Annual Report — Accounting Quality Signals, Related Party Disclosures, Auditor Signals, and Governance Watchpoints, generated with your own AI key.

Upgrade to PremiumCreate Free Account

📊 Sector KPIs

Industry-specific KPIs with historical trend — AI-extracted from investor presentations
🔒
Premium Feature
Industry-specific KPIs with historical trend across quarters — AI-extracted from investor presentations
Upgrade to Premium
Already a member? Log in

💼 Management Guidance

Revenue, loan book, NIM and other management targets — with hit/miss tracking
🔒
Premium Feature
Management guidance targets with historical hit/miss tracking — unlocked with Premium
Upgrade to Premium
Already a member? Log in

🎯 Thesis Tracker

Guidance vs Delivery — management track record
🔒
Premium Feature
Management guidance vs actual delivery — track whether revenue & PAT targets were Beat, Met or Missed across every reporting year
Upgrade to Premium
Already a member? Log in
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.

Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.

Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.

Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.